Excess fluid distribution affects tacrolimus absorption in peritoneal dialysis patients

Clinical and Experimental Nephrology

Volumn 17, Issue 5, 2013, Pages 743-749

  Sofue, Tadashi ^a   Inui, Masashi ^a   Kiyomoto, Hideyasu ^b   Moriwaki, Kumiko ^a   Hara, Taiga ^a   Yamaguchi, Kazunori ^c   Fukuoka, Noriyasu ^c   Banno, Kazuko ^d   Nishiyama, Akira ^a   Kakehi, Yoshiyuki ^a   Kohno, Masakazu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KAGAWA UNIVERSITY HOSPITAL   (Japan)

^d Shiga Pharmaceutical Association Proof Center   (Japan)

Author keywords

Excess fluid distribution; Living donor kidney transplantation; Peritoneal dialysis; Tacrolimus pharmacokinetics

Indexed keywords

BASILIXIMAB; GRACEPTOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; ASCITES; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GRAFT SURVIVAL; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; PERIOPERATIVE PERIOD; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONEAL FLUID; RETROSPECTIVE STUDY; SURVIVAL RATE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; BODY WEIGHT; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME; WATER-ELECTROLYTE IMBALANCE;

EID: 84887261310     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0764-6     Document Type: Article

References (27)

1. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50:235-42.
2. Edwards EB, Bennett LE, Cecka JM. Effect of HLA matching on the relative risk of mortality for kidney recipients: a comparison of the mortality risk after transplant to the mortality risk of remaining on the waiting list. Transplantation. 1997;64:1274-7.
3. Burra P, De Bona M. Quality of life following organ transplantation. Transpl Int. 2007;20:397-409.
4. Snyder JJ, Kasiske BL, Gilbertson DT, Collins AJ. A comparison of transplant outcomes in peritoneal and hemodialysis patients. Kidney Int. 2002;62:1423-30.
5. Konings CJ, Kooman JP, Schonck M, et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int. 2002;22:477-87.
6. John B, Tan BK, Dainty S, Spanel P, Smith D, Davies SJ. Plasma volume, albumin, and fluid status in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2010;5:1463-70.
7. Plum J, Schoenicke G, Kleophas W, et al. Comparison of body fluid distribution between chronic haemodialysis and peritoneal dialysis patients as assessed by biophysical and biochemical methods. Nephrol Dial Transplant. 2001;16:2378-85.
8. Van Biesen W, Williams JD, Covic AC, et al. Fluid status in peritoneal dialysis patients: the European Body Composition Monitoring (EuroBCM) study cohort. PLoS One. 2011;6:e17148.
9. Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2004;43:361-94.
10. Morrissey PE, Gohh R, Shaffer D, et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Transplantation. 1997;63:845-8.
11. Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation. 2009;88:S62-7.
12. Mourad M, Wallemacq P, De Meyer M, et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation. 2008;85:S19-24.
13. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003;14:1889-96.
14. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation. 2004;78:1182-7.
15. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4:914-9.
16. Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol. 2001;41:289-97.
17. Kimikawa M, Kamoya K, Toma H, Teraoka S. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant. 2001;15:324-9.
18. Sofue T, Inui M, Kiyomoto H, et al. Pre-existing arteriosclerotic intimal thickening in living-donor kidneys reflects allograft function. Am J Nephrol. 2012;36:127-35.
19. Jaeger JQ, Mehta RL. Assessment of dry weight in hemodialysis: an overview. J Am Soc Nephrol. 1999;10:392-403.
20. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753-60.
21. Rudant E, Bezie Y, Bonhomme-Faivre L, et al. Study of the correlation between MEIA and ELISA methods for FK 506 determination in liver transplant recipients. J Clin Pharm Ther. 1997;22:135-40.
22. Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: the CYP3A51 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation. 2005;79:499-502.
23. Iwasaki K, Shiraga T, Nagase K, et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos. 1993;21:971-7.
24. Chen YL, Hirabayashi H, Akhtar S, Pelzer M, Kobayashi M. Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;830:330-41.
25. Shimomura M, Masuda S, Saito H, et al. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. J Surg Res. 2002;103:215-22.
26. Tamura S, Tokunaga Y, Ibuki R, Amidon GL, Sezaki H, Yamashita S. The site-specific transport and metabolism of tacrolimus in rat small intestine. J Pharmacol Exp Ther. 2003;306:310-6.
27. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753-61. Technology